Lunsumio VELO, a CD20xCD3 bispecific antibody, is approved for relapsed or refractory follicular lymphoma after two or more systemic therapies. The GO29781 trial showed a 75% objective response rate ...
Nate, 55, a smoker, has seen three dermatologists for a rash that seems to be resistant to various treatments. He has complained that he has had a chronic bumpy and painful rash with pustules ...
The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or ...
The FDA has granted accelerated approval to subcutaneous treatment with mosunetuzumab (Lunsumio VELO™), a CD20xCD3 bispecific antibody, for adult patients with relapsed or refractory follicular ...
Roche’s FDA approval of Lunsumio VELO as a one-minute subcutaneous bispecific therapy for relapsed or refractory follicular ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELO™ ...
The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...
Feeling a little worse for wear is part and parcel of being a student. So when Zara Barton developed a cough and started to get itchy skin, she thought she was just suffering from a bout of “freshers ...
What Causes a Rash in Your Armpit? An armpit rash is more common than you might think. Your armpits probably come into contact with more chemicals each day than most other parts of your body. Don’t be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback